114 related articles for article (PubMed ID: 30615483)
1. Raloxifene nano-micelles effect on triple-negative breast cancer is mediated through estrogen receptor-β and epidermal growth factor receptor.
Greish K; Nehoff H; Bahman F; Pritchard T; Taurin S
J Drug Target; 2019 Sep; 27(8):903-916. PubMed ID: 30615483
[TBL] [Abstract][Full Text] [Related]
2. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
3. Styrene maleic acid-encapsulated RL71 micelles suppress tumor growth in a murine xenograft model of triple negative breast cancer.
Martey O; Nimick M; Taurin S; Sundararajan V; Greish K; Rosengren RJ
Int J Nanomedicine; 2017; 12():7225-7237. PubMed ID: 29042771
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer.
Pritchard T; Rosengren RJ; Greish K; Taurin S
J Drug Target; 2016; 24(5):441-9. PubMed ID: 26373825
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of raloxifene-targeted poly(styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing mice.
Enteshari S; Varshosaz J; Minayian M; Hassanzadeh F
Invest New Drugs; 2018 Apr; 36(2):206-216. PubMed ID: 29177974
[TBL] [Abstract][Full Text] [Related]
6. A novel role for raloxifene nanomicelles in management of castrate resistant prostate cancer.
Taurin S; Nehoff H; van Aswegen T; Rosengren RJ; Greish K
Biomed Res Int; 2014; 2014():323594. PubMed ID: 24689036
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and
Varshosaz J; Enteshari S; Hassanzadeh F; Hashemi-Beni B; Minaiyan M; Sadeghian-Rizi S
Anticancer Agents Med Chem; 2018; 18(14):2017-2031. PubMed ID: 30205803
[TBL] [Abstract][Full Text] [Related]
8. Selective Targeting of Breast Cancer by Tafuramycin A Using SMA-Nanoassemblies.
El-Deeb IM; Pittala V; Eltayeb D; Greish K
Molecules; 2021 Jun; 26(12):. PubMed ID: 34207832
[TBL] [Abstract][Full Text] [Related]
9. Tissue Distribution and Systemic Toxicity Evaluation of Raloxifene Targeted Polymeric Micelles of Poly (Styrene-Maleic Acid)-Poly (Amide- Ether-Ester-Imide)-Poly (Ethylene Glycol) Loaded With Docetaxel in Breast Cancer Bearing Mice.
Varshosaz J; Hassanzadeh F; Hashemi-Beni B; Minaiyan M; Enteshari S
Recent Pat Anticancer Drug Discov; 2019 Nov; 14(3):280-291. PubMed ID: 31538904
[TBL] [Abstract][Full Text] [Related]
10. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
11. CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer.
Wang Z; Sau S; Alsaab HO; Iyer AK
Nanomedicine; 2018 Jun; 14(4):1441-1454. PubMed ID: 29678787
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines.
Taurin S; Rosengren RJ
Med Oncol; 2022 Dec; 40(1):45. PubMed ID: 36494506
[TBL] [Abstract][Full Text] [Related]
13. Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression.
Taurin S; Allen KM; Scandlyn MJ; Rosengren RJ
Int J Oncol; 2013 Sep; 43(3):785-92. PubMed ID: 23842642
[TBL] [Abstract][Full Text] [Related]
14. The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer.
McNamara KM; Oguro S; Omata F; Kikuchi K; Guestini F; Suzuki K; Yang Y; Abe E; Hirakawa H; Brown KA; Takanori I; Ohuchi N; Sasano H
Breast Cancer Res Treat; 2017 Jan; 161(2):213-227. PubMed ID: 27848152
[TBL] [Abstract][Full Text] [Related]
15. A Role for ER-Beta in the Effects of Low-Density Lipoprotein Cholesterol and 27-Hydroxycholesterol on Breast Cancer Progression: Involvement of the IGF Signalling Pathway?
Mashat RM; Zielinska HA; Holly JMP; Perks CM
Cells; 2021 Dec; 11(1):. PubMed ID: 35011656
[TBL] [Abstract][Full Text] [Related]
16. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC
Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881
[TBL] [Abstract][Full Text] [Related]
17. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
18. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
[TBL] [Abstract][Full Text] [Related]
19. A novel compound LingH2-10 inhibits the growth of triple negative breast cancer cells in vitro and in vivo as a selective inverse agonist of estrogen-related receptor α.
Ning Y; Chen H; Du Y; Ling H; Zhang L; Chen L; Qi H; Shi X; Li Q
Biomed Pharmacother; 2017 Sep; 93():913-922. PubMed ID: 28715872
[TBL] [Abstract][Full Text] [Related]
20. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
